[1] Lee ECZ, Anand VV, Razavi AC, et al. The global epidemic of metabolic fatty liver disease. Curr Cardiol Rep,2024,26(4):199-210.
[2] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology ,2023,77(4): 1335-1347.
[3] Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int, 2020,14(2):259-269.
[4] Paik JM, Kabbara K, Eberly KE, et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology,2022,75(5):1204-1217.
[5] Hartmann P, Zhang X, Loomba R, et al. Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019. Hepatology,2023,78(4):1168-1181.
[6] Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, et al. Epidemiologic, genetic, pathogenic, metabolic, epigenetic aspects involved in NASH-HCC: Current therapeutic strategies. Cancers, 2023, 15(1): 23.
[7] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol,2021,18(4): 223-238.
[8] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol,2020,5(3):245-266.
[9] Tran S, Zou B, Lee K, et al. Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real-world U.S. patients, 2003-2021. Aliment Pharmacol Ther,2024[ahead of print].
[10] Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol, 2013,59(3):550-556.
[11] Carneiro CRG, Ayres ABS, Gestic MA, et al. Association of histopathological and biochemical aspects of NAFLD with the severity of liver fibrosis in individuals with obesity: cross-sectional study. Obes Surg,2024,34(5):1569-1574.
[12] Alexopoulos AS, Crowley MJ, Wang Y, et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology,2021, 74(3): 1220-1233.
[13] Ke P, Xu M, Feng J, et al. Association between weight change and risk of liver fibrosis in adults with type 2 diabetes. J Glob Healt, 2023,13: 4138.
[14] Biswas S, Vaishnav M, Farooqui N, et al. Impact of body mass index on disease progression and outcomes in patients with nonalcoholic fatty liver disease. Postgrad Med J, 2023,99(1176): 1094-1103.
[15] Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int,2020,14(6): 889-919.
[16] Lim GEH, Tang A, Ng CH, et al. An observational data Meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol, 2023,21(3): 619-629.
[17] Lee H, Lee Y, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study. Clin Gastroenterol Hepatol, 2021,19(10): 2138-2147.
[18] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol, 2024, 29(1): 101133.
[19] Younossi ZM, Paik JM, Stepanova M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol, 2024,80(5):694-701.
[20] 中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会和中国研究型医院学会肝病专业委员会.瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版).中华肝脏病杂志,2019,27(3):182-191.
[21] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology (New York, N.Y. 1943), 2019,156(6): 1717-1730.
[22] Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019,17(1): 156-163.
[23] Zenovia S, Stanciu C, Sfarti C, et al. Vibration-controlled transient elastography and controlled attenuation parameter for the diagnosis of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Diagnostics (Basel) , 2021, 11(5): 787.
[24] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings. Endoc Pract, 2022,28(5): 528-562.
[25] Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis . J Hepatol, 2021, 75(4): 770-785.
[26] Liang JX, Ampuero J, Niu H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol, 2023,79(3):592-604.
[27] Gidener T, Ahmed OT, Larson JJ, et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin Gastroenterol Hepatol, 2021, 19(9): 1915-1924.
[28] Roy A, Verma N, Jajodia S, et al. Magnetic resonance elastography (MRE) outperforms acoustic force radiation impulse (ARFI) in predicting oesophageal varices in obese NAFLD cirrhosis. Abdom Radiol (NY),2024[ahead of print].
[29] Loomba R, Wolfson T, Ang B, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology, 2014,60(6):1920-1928.
[30] Bedossa P, Patel K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology,2016,150(8):1811-1822,e4.
[31] Kim BK, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol,2022,77(6):1482-1490.
[32] Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology,2017, 66(5): 1486-1501.
[33] Mózes FE, Lee JA, Vali Y, et al. Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis. Liver Int, 2024[ahead of print].
[34] Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol,2020,5(4):362-373.
[35] Noureddin M, Truong E, Gornbein JA, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol, 2022,76(4):781-787.
[36] Chen YT, Chen TI, Yang TH, et al. Long-term risks of cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes. Am J Gastroenterol ,2024[ahead of print].
[37] Cholankeril G, Perumpail RB, Pham EA, et al. Nonalcoholic fatty liver disease: epidemiology, natural history, and diagnostic challenges. Hepatology, 2016, 64(3): 954.
[38] Tan HK, Teng MLP, Soh AYS, et al. Poor outcomes of cirrhosis due to nonalcoholic steatohepatitis compared with hepatitis B after decompensation with ascites. Am J Gastroenterol, 2021,116(7):1437-1446.
[39] Canbay A, Kachru N, Haas JS, et al. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther,2020,52(7):1185-1194.
[40] Sanyal AJ, Foucquier J, Younossi ZM, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol,2023,78(2): 247-259.
[41] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[42] Kenneally S, Sier JH, Moore JB. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterol, 2017, 4(1): e139.
[43] Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci, 2014,59(8): 1958-1965.
[44] Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology ,2023, 78(6): 1896-1906.
[45] Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology, 2020,71(2):495-509.
[46] Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology ,2014, 60(6): 2008-2016.
[47] Vilar Gomez E, Vuppalanchi R, Desai AP, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Aliment Pharmacol Therap, 2019, 50(3): 317-328.
[48] Loomba R AMAM, Investigators N. Semaglutide 2、4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol, 2021,6(8): 511-522.
[49] Izzy M, Angirekula M, Abu Dayyeh BK, et al. Bariatric surgery proves long-term benefit in patients with cirrhosis. Gastroenterol Rep,2021, 9(3): 252-256.
[50] Vijayaraghavan R, Sarin SK, Bharadwaj A, et al. Intragastric balloon in obese compensated nonalcoholic steatohepatitis cirrhosis patients is safe and achieves significant weight reduction at 6-months. Dig Dis Sci, 2023,68(3): 1035-1041. |
